Gnatophyma and Otophyma

2009 ◽  
Vol 13 (5) ◽  
pp. 266-272 ◽  
Author(s):  
Navid Ezra ◽  
Joseph F. Greco ◽  
Jennifer C. Haley ◽  
Melvin W. Chiu
Keyword(s):  
African American ◽  
African American Male ◽  
Line Treatment ◽  
Epidermal Hyperplasia ◽  
First Line ◽  
The Past ◽  
The Face ◽  
History Of ◽  
End Stage ◽  
First Line Treatment

Background: Phymas are slowly progressive, disfiguring disorders of the face and ears that represent the end stage of rosacea. The most common phyma is rhinophyma, yet similar swellings may occur on the chin (gnatophyma), forehead (metophyma), one or both ears (otophyma), and eyelids (blepharophyma). Objective: Unlike rhinophyma, otophyma is rarely seen. We report two rare phymas: a case of gnatophyma and a case of otophyma. Methods: A 56-year-old African American man presented with a history of bumps on his chin that had begun about 7 years earlier. Physical examination was remarkable for lobulated plaques on the chin, coalescing into hypertrophic nodules and dilated pores. A 73-year-old African American male presented with bilateral cauliflower-like earlobe growths for the past 17 years. Results: A skin biopsy was performed for each patient demonstrating cystic follicular dilatation with keratin plugging, dermal scarring, psoriasiform epidermal hyperplasia, and chronic inflammation of some of the follicles. Conclusion: This case report describes a relatively rare gnatophyma and otophyma. Surgical management is well accepted as the best mode of therapy to treat rhinophyma and is becoming a first-line treatment for all phymas.

FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15007-e15007
Author(s):  
F. Giuliani ◽  
F. De Vita ◽  
V. Lorusso ◽  
S. Cinieri ◽  
I. Nugnes ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Survival Data ◽  
Advanced Colorectal Cancer ◽  
Median Number ◽  
Line Treatment ◽  
First Line ◽  
Bleeding Events ◽  
History Of ◽  
Optimal Regimen ◽  
First Line Treatment

e15007 Background: The addition of Bev to IFL obtained better OS and RR than chemotherapy alone. However IFL is not considered an optimal regimen and is certainly more toxic than FOLFIRI. To investigate the activity and efficacy of the addition of Bev to FOLFIRI, the GOIM started the following phase II study. Methods: seventy-two untreated pts with histologically/citologically confirmed diagnosis of colorectal cancer, with at least one measurable disease, age > 18 yrs, PS < 2 (ECOG), adequate bone marrow reserve and hepatic and renal function, with no history of cardiovascular disease, thromboembolic events or coagulative disorders and who signed informed written consent, were enrolled and received the following treatment: CPT-11 at 180 mg/m/mq on day 1, FA at 100 mg/mq as 2h infusion on days 1–2, FU at 400 mg/mq bolus on days 1–2 and FU at 600 mg/mq as 22h infusion on days 1–2 (FOLFIRI) plus Bev at 5 mg/Kg on day 1, every two weeks. A maximum of 12 cycles of chemotherapy was planned and a maintenance with Bev for 6 months was permitted. The evaluation of activity (Recist criteria) was performed every 4 cycles Results: all the enrolled pts were evaluable for activity and safety. Their main characteristics were M/F: 38/34; median PS: 0; median age 60 (range 33–73); primary site colon/rectum: 50/22 (69.4%/30.6%); main sites of disease liver: 50 (69.4%), lung: 18 (25%), lymph nodes: 19 (26.4%); synchronous/metacronous disease: 55/17 (77.7%/22.3%); multiple/single lesions: 40/32 (55.5%/44.5%).Seven (9.6%) CR, 25 (34.8%) PR, 33 (45.8%) SD and 7 PRO were observed for an ORR of 44.4% and a disease control of 90.3%. The response rate according to the main sites of disease were: liver 25/50 (50%), lung 6/18 (33.3%). The median number of administered cycle were 9 and the median TTP was 10.0 months. The main haematologic side-effects (% G3–4 NCI criteria) were: neutropenia 11%, thrombocytopenia 2.7% and anemia 4.7%, while diarrhea affected only 2.7% of pts; hypertension, thromboembolic and bleeding events were observed in 2.7%, 1.3% and 1.3% respectively. Conclusions: the addition of Bev to FOLFIRI is an active and effective first-line treatment in ACC with a good safety profile. Survival data will be presented during the meeting. No significant financial relationships to disclose.

scholarly journals Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin

2008 ◽  
Vol 5 (3) ◽  
pp. 71-73
Author(s):  
Haroon Rashid Chaudhry ◽  
Nadia Arshad ◽  
Saima Niaz ◽  
Tahir Suleman ◽  
Khalid A. Mufti
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Chronic Illness ◽  
Economic Consequences ◽  
Line Treatment ◽  
First Line ◽  
Antipsychotic Medications ◽  
The Past ◽  
Atypical Antipsychotic Medications ◽  
First Line Treatment

Schizophrenia is a chronic illness with a lifetime prevalence of 1% and with serious physical, social and economic consequences. Over the past decade, atypical antipsychotic medications have become the first-line treatment for schizophrenia (Breier et al, 2005).

scholarly journals Profile and evolution of the chemosusceptibility of falciparum malaria imported into France in 2000

2002 ◽  
Vol 7 (7) ◽  
pp. 113-118 ◽  
Author(s):  
P Ralaimazava ◽  
R Durand ◽  
N Godineau ◽  
A Keundjian ◽  
Z Jezic ◽  
...  
Keyword(s):  
Falciparum Malaria ◽  
Imported Malaria ◽  
Line Treatment ◽  
First Line ◽  
The Past ◽  
First Line Treatment

In 2000, the chemosusceptibility of imported malaria was stable in France. All countries of infection considered, the bi-resistance to chloroquine and cycloguanil has not changed from 1996 to 2000. The monotherapy using quinine or mefloquine remains the first-line treatment to falciparum malaria. Resistance to these two antimalarials is rare in Africa and has not evolved over the past 15 years.

scholarly journals Psoriasis - A Report of Disease Mimicry

2020 ◽  
Vol 18 (2) ◽  
Author(s):  
Mohd Shaiful Ehsan Shalihin ◽  
Mohd Aizuddin Abd Rahman
Keyword(s):  
Case Report ◽  
Joint Pain ◽  
Coal Tar ◽  
Skin Condition ◽  
Line Treatment ◽  
First Line ◽  
Recent Exposure ◽  
History Of ◽  
Acute Condition ◽  
First Line Treatment

Introduction: Psoriasis is a chronic, noncontagious, multifactorial inflammatory skin condition that has several subtypes. Therefore, prior to actual diagnosis, it may mimics other similar illnesses. In acute condition, it typically presents with erythroderma macules associated with pain and itchiness rather than  hypopigmented and numbness lesions that supposedly occurs in post-treatment or post-acute phase, rather than as initial presentation. Case report: We report a case of 18-year-old girl, who presented with nonspecific localized hypopigmented rash over her forehead and scalp associated with numbness for three weeks duration. She had no itchiness or rashes elsewhere. She had no history of atopy or recent exposure to new cosmetics. She had no joint pain or hair loss. She had no recent contact with anyone with similar lesion. No significant similar history among family members. Clinically, there is reduced in both soft touch and pin-prick sensation over affected areas. We refer this case to dermatologist with possibility of leprosy in view of her reduced sensation over the lesion. To our surprise, the skin biopsy revealed supportive points towards psoriasis. She responds well towards coal tar and topical corticosteroids-the first line treatment of psoriasis. Her numbness has also resolved. This case highlights that psoriasis do presents with localized numbness in which its diagnosis should be take into consideration before confining the disease towards leprosy only.

scholarly journals Carbamazepine and Hyperpigmentation in a Young Woman: A Case Report

2020 ◽  
Author(s):  
Mona Talaschian ◽  
Anahita Sadeghi ◽  
Sara Pakzad
Keyword(s):  
Bipolar Disorder ◽  
Young Woman ◽  
Hepatic Metabolism ◽  
Line Treatment ◽  
First Line ◽  
Cutaneous Side Effects ◽  
History Of ◽  
And Control ◽  
Important Drug ◽  
First Line Treatment

Carbamazepine (CBZ) is an effective and first-line treatment for trigeminal neuralgia and has a key place in the management of epilepsy and bipolar disorder. There is the possibility ofclinically important drug interactions because CBZ may induce the hepatic metabolism of other drugs or, conversely, other drugs may induce or inhibit CBZ metabolism. The drug isa member of a big group of antiepileptic drugs that are widely used to prevent and control seizures. It has been associated with several cutaneous side effects. In this case, we reporta young woman who presented with dyspnea, weight loss, pancytopenia, abdominal pain, oligomenorrhea, and two weeks history of hyperpigmented lesions over her face, neck, andtwo hands. She had a history of seizures and did well on carbamazepine for the last 7 months. Carbamazepine was discontinued and she was treated with local emollients. The lesions werepartially improved in 2 weeks.

Chronic Lymphocytic Leukemia (CLL): First-Line Treatment

Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 285-291
Author(s):  
Michael Hallek ◽  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Current Knowledge ◽  
Lymphocytic Leukemia ◽  
Line Treatment ◽  
First Line ◽  
The Past ◽  
Therapeutic Compounds ◽  
First Line Treatment

For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is intended to summarize the current knowledge on first-line treatment of CLL.

Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. TPS462-TPS462 ◽  
Author(s):  
Tanios S. Bekaii-Saab ◽  
Juan W. Valle ◽  
Mitesh J. Borad ◽  
Davide Melisi ◽  
Arndt Vogel ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Genetic Alterations ◽  
Current Evidence ◽  
Survival Duration ◽  
Line Treatment ◽  
First Line ◽  
Phase 3 ◽  
History Of ◽  
First Line Treatment

TPS462 Background: Dysregulation of fibroblast growth factor receptor (FGFR) signaling by FGFR genetic alterations is implicated in many cancers, including cholangiocarcinoma (CCA). FGFR2 translocations with fusion partners occur in ≈10% to 20% of intrahepatic CCA tumors. Pemigatinib is a selective oral inhibitor of FGFR-1, 2, 3. Preliminary data from the ongoing phase 2 study show efficacy and tolerable safety in patients (pts) with CCA with FGFR2 translocations. We present the design for a phase 3, open-label, randomized trial investigating pemigatinib monotherapy versus gemcitabine plus cisplatin chemotherapy in the first-line treatment of pts with advanced/metastatic or unresectable CCA with FGFR2 rearrangement. Methods: Eligible pts (target, N = 432) are ≥ 18 years (≥ 20 years for Japanese pts) and have ECOG performance status ≤ 1 and histologically confirmed advanced (locally advanced, metastatic, or recurrent) CCA with a documented FGFR2 rearrangement. Key exclusion criteria include prior systemic therapy, excluding adjuvant/neoadjuvant treatment completed ≥ 6 months before enrollment; current evidence of clinically significant corneal or retinal disorder; history of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues; and known, untreated CNS metastases or history of uncontrolled seizures. Pts are randomized 1:1 and stratified by geographic region and tumor burden into 2 treatment groups: pemigatinib starting dose 13.5 mg once daily continuously on a 3-week cycle; or gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) administered intravenously on days 1 and 8 of every 3-week cycle for up to 8 cycles until disease progression or unacceptable toxicity. Crossover to pemigatinib may be allowed once progressive disease is confirmed. The primary endpoint is progression-free survival (based on independent central review using RECIST v1.1). Secondary endpoints include overall response rate, overall survival, duration of response, disease control rate, safety and tolerability, and impact on quality of life. Clinical trial information: NCT03656536.

Sign in / Sign up

Export Citation Format

Share Document